Press Release Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | View All
Press Releases |
Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)December 28, 2011Enobia Pharma Raises US $40 millionAugust 08, 2011Enobia Announces Completion of Enrollment in Third Phase II Hypophosphatasia Study of ENB-0040, a Bone Targeted Enzyme Replacement TherapyFebruary 24, 2011Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement TherapyJanuary 10, 2011Enobia Reports Positive Results for Phase II Trial of ENB-0040 in Juvenile HypophosphatasiaSeptember 24, 2010Enobia Provides Update on Progress with ENB-0040, a Bone-targeted Enzyme Replacement Therapy for HypophosphatasiaSeptember 08, 2010ENB-0040, A Bone Targeted Enzyme Replacement Therapy, Shows Promise in Children with HypophosphatasiaJune 21, 2010Enobia Presents Results from Hypophosphatasia Impact Patient SurveyMarch 29, 2010Enobia Expands Clinical Program for ENB-0040, a Bone-targeted Enzyme Replacement Therapy for HypophosphatasiaNovember 02, 2009Enobia Announces Positive Clinical Results with ENB-0040, a Bone Targeted Enzyme Replacement Therapy for HypophosphatasiaSeptember 14, 2009